Distributing the future: The weak justifications for keeping human genomic databases secret and the challenges and opportunities in reverse engineering them

@inproceedings{Angrist2014DistributingTF,
  title={Distributing the future: The weak justifications for keeping human genomic databases secret and the challenges and opportunities in reverse engineering them},
  author={Misha Angrist and Robert Cook-Deegan},
  booktitle={Applied & translational genomics},
  year={2014}
}
Myriad Genetics, founded in 1991 as a spin-off from the cancer genetics epidemiology unit at the University of Utah and initially funded in part by publicmoney, went on to build amulti-billion-dollar business bydiscovering andpatenting two genes that,whenmutated, predispose to hereditary breast and ovarian cancer (HBOC) (Williams-Jones, 2002; Allison, 2014). While Myriad's reputation as a competent test provider was generally exemplary and there was no apparent price premium attributable to the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 32 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Myriad Genetics' (MYGN

  • S. Gleason, Meldrum, P.D
  • CEO Peter Meldrum on Q4 2014 Results — Earnings…
  • 2014
Highly Influential
9 Excerpts

DNA project aims to make public a company's data on cancer

  • G. Kolata
  • genes. N.Y. Times (12 April,
  • 2013
Highly Influential
5 Excerpts

Genetics lab refuses to share data that could save lives. Jew. Daily Forw

  • K. I. Tucker
  • 2014
Highly Influential
6 Excerpts

Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes

  • D. Pruss, B Morris
  • Breast Cancer Res. Treat
  • 2014

Similar Papers

Loading similar papers…